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ABSTRACT The protozoan parasite Toxoplasma gondii secretes proteins from spe-
cialized organelles, the rhoptries, and dense granules, which are involved in the
modulation of host cell processes. Dense granule protein GRA15 activates the nu-
clear factor kappa B (NF-B) pathway, which plays an important role in cell death,
innate immunity, and inflammation. Exactly how GRA15 activates the NF-B pathway
is unknown. Here we show that GRA15 interacts with tumor necrosis factor receptor-
associated factors (TRAFs), which are adaptor proteins functioning upstream of the
NF-B transcription factor. We identified several TRAF binding sites in the GRA15
amino acid sequence and showed that these are involved in NF-B activation. Fur-
thermore, a TRAF2 knockout cell line has impaired GRA15-mediated NF-B activa-
tion. Thus, we determined the mechanism for GRA15-dependent NF-B activation.
IMPORTANCE The parasite Toxoplasma can cause birth defects and severe disease
in immunosuppressed patients. Strain differences in pathogenicity exist, and these
differences are due to polymorphic effector proteins that Toxoplasma secretes into
the host cell to coopt host cell functions. The effector protein GRA15 of some Toxo-
plasma strains activates the nuclear factor kappa B (NF-B) pathway, which plays an
important role in cell death, innate immunity, and inflammation. We show that
GRA15 interacts with TNF receptor-associated factors (TRAFs), which are adaptor pro-
teins functioning upstream of the NF-B transcription factor. Deletion of TRAF-
binding sites in GRA15 greatly reduces its ability to activate the NF-B pathway, and
TRAF2 knockout cells have impaired GRA15-mediated NF-B activation. Thus, we de-
termined the mechanism for GRA15-dependent NF-B activation.
KEYWORDS NF-B pathway, TRAF2, TRAF6, Toxoplasma gondii, host-pathogen
interactions
Toxoplasma is an obligate intracellular protozoan parasite that can cause congenitaltoxoplasmosis, opportunistic infections in immunosuppressed patients, and ocular
disease (1). There are many different Toxoplasma strains, and dramatic strain differences
in virulence and modulation of the host cell exist (2). In Europe and North America,
most human infections are caused by type II strains, but type III, type 12, and type I
strains are also present in these regions (3, 4). To modulate its host cells, Toxoplasma
secretes specialized effector proteins called ROPs and GRAs from organelles known as
the rhoptries and dense granules, respectively (2). Some GRAs are secreted beyond the
parasitophorous vacuole (PV) membrane (PVM) into the host cell cytosol, most likely
through a PVM-localized translocon consisting of the Toxoplasma proteins MYR1/2/3 (5,
6), and modulate host cell signaling pathways (7–10). Other GRAs are inserted in the
parasitophorous vacuole membrane (PVM), with one part facing the host cytoplasm to
interact with host proteins, often in a strain-specific manner. For example, GRA6 from
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type I and III strains (GRA6I/III) activates the NFAT4 (nuclear factor of activated T cells)
transcription factor (11), MAF1bI/III (mitochondrial association factor 1bI/III) mediates
host mitochondrial association with the PVM, GRA7 binds to IRGa6 (GTP-bound
immunity-related GTPase a6) (12, 13), and GRA15II activates the NF-B pathway (14).
The NF-B pathway consists of the canonical and alternative pathways, with the
former involved in innate, inflammatory, and adaptive immune responses, while the
latter is involved in the regulation of lymphoid organ development, B cell function, and
adaptive immunity. Five NF-B genes can produce five transcription factors (RelA, cRel,
RelB, p50, p52), which can form 15 transcription factors through homo- and het-
erodimerization [e.g., RelA (p65/p50)] (15). Given the crucial role NF-B plays in cell
death, inflammation, and the immune response, many pathogen effector proteins
target the NF-B pathway (16). Toxoplasma GRA15 accounts for differences in NF-B
activation between different isolates of the type I clonal lineage (RH and GT1) (17) and
between type II and type III strains upon infection (14). GRA15 can stimulate the host
innate immune response through mediating human monocyte secretion of the NF-B-
dependent cytokine interleukin-1 (IL-1) (18), the induction of IL-12 secretion by
murine macrophages (14, 19), and upregulation of the CD40 cell surface receptor on
murine macrophages, which leads to IL-12 production and induction of the interferon
gamma (IFN-) response (20). GRA15-mediated inflammation can also lead to miscar-
riage and stillbirth in pregnant mice (21). The cytokine IFN- upregulates the large
family of GTPases named the guanylate binding proteins (GBPs), which can bind to the
PVM and mediate its destruction and subsequently that of the parasite inside (22).
GRA15 enhances the recruitment of murine GBP1 to the PVM through an unknown
mechanism (23, 24). In a human monocyte-hepatocyte coculture system, it was recently
shown that GRA15-induced IL-1 secretion by monocytes leads to inducible nitric oxide
synthase (iNOS) upregulation in hepatocytes. The nitric oxide (NO) produced inhibits
the IFN--induced enzyme indoleamine-2,3-deoxygenase (IDO), which degrades
L-tryptophan for which Toxoplasma is auxotrophic, resulting in enhanced parasite
growth (25). Thus, GRA15 has pleiotropic effects on host immune responses to Toxo-
plasma.
Strain differences in the activation of NF-B could be due to GRA15 amino acid
differences (14), differences in GRA15 expression levels (19), other effectors that mod-
ulate the NF-B pathway (19), or a combination of all of these. GRA15-dependent NF-B
activation was Myd88/TRIF (adaptors directly downstream of Toll-like receptors [TLRs])
independent but partially TRAF6 (tumor necrosis factor [TNF] receptor-associated factor
6) dependent (14). However, the exact mechanism of GRA15-dependent NF-B activa-
tion remains unclear. Here we show that both type II and type III GRA15 proteins are
sufficient to cause NF-B activation upon ectopic expression. Using coimmunoprecipi-
tation, we identify host proteins interacting with GRA15, including TRAFs, which are key
intermediates in the NF-B pathway that can transduce activating signals through the
assembly of signaling complexes, which eventually leads to activation of the NF-B
pathway (26). We also identified particular GRA15 regions and GRA15 TRAF-binding
sites that are important for NF-B activation. Thus, we have identified the mechanism
by which GRA15 activates the NF-B pathway.
RESULTS
GRA15 from the type II and type III strains activates NF-B when expressed
ectopically. Type III and type I (GT1 strain) GRA15 protein sequences contain 635
amino acids (aa), while type II GRA15 has 550 aa due to a deletion at the C terminus
(Fig. 1A). The type I RH strain has a mutation in the GRA15 gene, leading to a frameshift
and early stop codon (14). We observed that even though GRA15 is a relatively
disordered protein (27), the amino acids 10 to 29 and 50 to 72 are predicted to be part
of two transmembrane regions (Fig. 1B), while no classical signal peptide sequence was
predicted (28). Even though no classical signal peptide was predicted, similar to what
has been observed for GRA6 (29), we have previously shown that GRA15 is secreted into
the PV and localizes to the PVM (14). We, therefore, believe that the first 29 amino acids
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FIG 1 Ectopic expression of either GRA15II or GRA15III is sufficient to activate NF-B. (A) Schematic showing RH (GRA15), GRA15II, and GRA15III protein sequence
and alignment. Red boxes indicate two predicted transmembrane domains. The blue box indicates the specific region of GRA15III. (B) Structural disorder
predictor for GRA15III using the software Protein DisOrder prediction System (PrDOS), with a double asterisk indicating increased structural order across residues
50 to 72. Two blue dashed lines indicate the region specific for GRA15III. (C) TREX-293 cells overexpressing GRA15II and RA15III were induced with tetracycline
(1 g/ml) for 24 h, fixed with formaldehyde, and stained for p65 (red), HA (green), and Hoechst (blue). The scale bar represents 10 m. Arrows indicate nuclei
(Continued on next page)
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function as a nonclassical signal peptide. We previously showed that type II strains
activate NF-B more strongly than type III strains (14). We have also shown that other
Toxoplasma-secreted effectors such as ROP16 and ROP38 can inhibit the NF-B signal-
ing pathway and that GRA15 expression levels also seem to affect NF-B activation (19).
It is therefore unclear if different GRA15 sequences differ in their capacity to activate
NF-B. We previously showed that GRA15II is sufficient for activating the NF-B path-
way by transfecting HeLa cells with a plasmid capable of expressing a GRA15II-GFP
(green fluorescent protein) fusion protein (14). However, we were unable to generate
stable expression cell lines, likely because the expression of GRA15II was toxic to the
cells (not shown). Therefore, to determine if GRA15II and GRA15III can both activate the
NF-B pathway, we engineered stable HEK293-derived (TREX-293) cell lines expressing
GRA15II (TGME49_275470, from residues 51 to 550 to exclude the putative signal
peptide) or GRA15III (from residues 51 to 631 to exclude the putative signal peptide)
with a C-terminal hemagglutinin (HA)-FLAG double-epitope tag under the control of
the tetracycline operator. In TREX-293 cells expressing GRA15II or GRA15III, expression
of these proteins was strictly regulated by tetracycline. GRA15II and GRA15III seemed to
have a predominantly cytoplasmic localization (Fig. 1C), although no further attempts
were made to determine the exact subcellular localization of these proteins. p65
nuclear translocation indicated that upon induction by tetracycline, both GRA15II and
GRA15III were able to activate the NF-B pathway (Fig. 1C; see Fig. S1A in the
supplemental material). We noted that under tetracycline induction, the observed
molecular weights of GRA15II and GRA15III (75 and 90 kDa, respectively), when
ectopically expressed, were higher than the expected predicted sizes (57 and 66 kDa,
respectively [https://www.expasy.org]) (Fig. 1D). We also immunoblotted for the en-
dogenous GRA15 in human foreskin fibroblasts (HFFs) infected with strains expressing
either a type II GRA15 (GRA15II) or a type I/III GRA15 (GRA15I/III) and observed a similar
increase in GRA15 size compared to the expected GRA15 size (Fig. 1E). Thus, the larger
than the expected size of GRA15 expressed by Toxoplasma is not caused by parasite-
mediated modification(s) of GRA15. Most likely, it is the particular amino acid compo-
sition of GRA15, which is enriched in Pro, Ser, and Thr, that makes it run slower than
expected on an SDS-PAGE gel. To determine more quantitatively if there were any
differences in the capacity to activate the NF-B pathway between these two proteins,
we transiently transfected HEK293 NF-B reporter cells (luciferase/GFP) with both
GRA15 plasmids. After quantification of the luciferase activity, both proteins activated
the NF-B reporter significantly compared to the empty vector. We did not observe a
significant difference between GRA15II and GRA15III in NF-B activation (Fig. 1F). The
amounts of protein in the transient transfections were similar (Fig. S1B). These results
indicate that both GRA15II and GRA15III can activate NF-B.
Identification of the GRA15 sequence necessary for NF-B activation. BLAST
searches with the GRA15 protein sequence did not detect homology to any known
proteins or any known protein domains. Therefore, to determine which region of
GRA15 is required for GRA15-dependent NF-B activation, we engineered GRA15 N-
and C-terminal truncation mutants. We cloned the full-length GRA15II-51–550 without
the putative signal peptide (schematic GRA15II [Fig. 2A]), C-terminally truncated GRA15
variants (51–338, 51–479, 51–517, and 51–527), and N-terminally truncated GRA15
variants (80–550, 170–550, and 270–550) fused to GFP in a mammalian expression
vector. We transiently transfected both full-length and truncated GRA15 mutants in an
HEK293 NF-B reporter cell line and measured NF-B activation. Based on the detection
FIG 1 Legend (Continued)
of cells expressing GRA15 and containing nuclear p65. Dashed arrows indicate nuclei of cells containing no nuclear p65. IB, immunoblot. (D) Immunoblot of
TREX-293 GRA15II- and TREX-293 GRA15III-overexpressing cell lysates induced with tetracycline for 24 h, using an antibody against the HA tag. GAPDH antibody
was used as a loading control. (E) Immunoblot on extracellular parasite lysates of type II and type III strains using an antibody against the C terminus of
endogenous GRA15, with SAG1 antibody as a loading control. (F) NF-B reporter HEK293 cells transfected with pcDNA GRA15II and GRA15III or empty vector.
The graph shows average luciferase activity from the cell lysate from three independent experiments (n  3), and error bars represent SD. The asterisk indicates
significantly higher levels of luciferase activity compared to the empty vector. P  0.0012 for GRA15II and P  0.0006 for GRA15III by one-way ANOVA with
Dunnett’s multiple-comparison test.
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of GFP expression, all constructs were successfully expressed and seemed to localize to
the host cytoplasm (not shown). The two largest GRA15 C-terminal truncations showed
less activation of NF-B, but this only reached significance for the GRA1551–338 con-
struct. The N-terminal truncation mutants had significantly decreased NF-B activation
compared to full-length GRA15II-51–550 (Fig. 2B). The N-terminal mutant with the
smallest region truncated is GRA15II-80–550, indicating that residues 51 to 79 are
necessary for GRA15-dependent NF-B activation. To ensure that the decrease in NF-B
activation was not due to lack of protein expression, we immunoblotted for GRA15
upon transient transfection of HEK293 cells and observed that the N-terminal GRA15
mutants were more strongly expressed than the full-length GRA15II-51–550 (Fig. 2C). We
were not able to detect the two largest C-terminal GRA15 mutants (GRA1551–479 and
GRA1551–338) on Western blots because the GRA15 antibody was raised against resi-
dues 493 to 510. Thus, the decrease in NF-B activation is specific to the missing
sequences in the N-terminal GRA15 sequences and not because of protein expression
differences. We observed that the second predicted transmembrane (amino acids 51 to
72) (Fig. 1B) seems to be important for GRA15-mediated activation of NF-B.
Identification of GRA15 candidate host-interacting proteins. Even though there
is evidence that GRA15 requires TRAF6 to achieve full NF-B activation (14), it is unclear
FIG 2 The N-terminal region of GRA15II is required for full NF-B activation. (A) Schematic showing GRA15II N- or C-terminal truncation
mutants. The red box indicates the second predicted transmembrane domain. The purple box indicates the two TRAF2-binding sites,
and the brown box indicates the unique TRAF6-binding site. (B) Transient transfections of the NF-B reporter cell line with GRA15II N-
or C-terminal truncation mutants. The graph shows average luciferase fold changes across three independent experiments (n  3), in
comparison to empty vector-transfected cells, and error bars represent SD. The asterisk indicates significantly higher levels of luciferase
activity compared to cells transfected with GRA15II-51–550. P 0.03 for GRA1551–338, P 0.04 for GRA1580–550, P 0.03 for GRA15170–550,
and P  0.02 for GRA270–550 by one-way ANOVA with Dunnett’s multiple-comparison test. (C) NF-B reporter cell lines were transiently
transfected with GRA15 N- or C-terminal truncation mutants and immunoblotted with an antibody against GRA15 (raised against
residues 493 to 510) (top panel) and GAPDH (bottom panel) for the loading control.
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whether GRA15 directly interacts with TRAF6 or acts indirectly through TRAF6 to cause
NF-B activation. Therefore, to determine potential host proteins that interact with
GRA15 or are in the same complex with GRA15, we harvested whole-cell lysates from
TREX-293 GRA15II 16 h postinduction with tetracycline. As a negative control, we used
TREX-293 expressing ROP38I. These lysates were then subjected to immunoprecipita-
tion using the HA antibody, and immunoprecipitates were probed with HA antibody to
confirm the presence of each protein in the immunoprecipitates (Fig. 3A). The immu-
noprecipitates were directly sent for mass spectrometry analysis. To control for poten-
tial spurious interactions detected through mass spectrometry, we refined the list of
proteins to those identified only in GRA15II-overexpressing conditions and excluded
proteins detected in immunoprecipitates from ROP38I-overexpressing conditions. We
identified a list of candidate host proteins that could have direct interactions with
GRA15II (Table 1). In the TREX-293 GRA15II-expressing cells, we observed that TRAF2,
FIG 3 Immunoprecipitation of TREX-293 GRA15II and RH-GRA15II. TREX-293 GRA15II and ROP38I were
induced with tetracycline (1 g/ml), harvested 16 h postinduction (A, B), or infected for 8 h with RH
parasites expressing HA-tagged GRA15 (C). The cells were lysed for HA immunoprecipitation with
magnetic beads. Immunoblotting was performed on 10% input and 30 l of the HA magnetic beads with
(A) HA antibody, (B) TRAF2, TRAF3, and TRAF6 antibodies, or (C) HA, TRAF2, and TRAF6 antibodies and
lamin A as a loading control of the 10% input.
TABLE 1 Identification of host interaction partners of GRA15a
Protein MW (kDa)
Spectrum counts
Normalized total
spectra
GRA15 ROP38 GRA15 ROP38
TNF receptor-associated factor 6
(TRAF6)
60 114 0 151 0
TNF receptor-associated factor 2
(TRAF2)
56 106 0 141 0
Baculoviral IAP repeat-containing
protein 2 (BIRC2)
70 32 0 44 0
TNF receptor-associated factor 3
(TRAF3)
64 2 0 3 0
aShown are results from immunoprecipitation (IP) with HA antibody on stable HEK293-derived (TREX-293)
cell line expressing GRA15II or ROP38 with a C-terminal HA-FLAG epitope tag under the control of the
tetracycline operator. The table represents the putative host interaction partners identified through mass
spectrometry analysis specific to GRA15 IP. The spectrum counts indicate the total number of peptide
spectra used to identify the protein. The normalized total spectra indicate the normalization of the
spectrum counts of protein peptides by the total number of spectra in the sample. MW, molecular weight.
Sangaré et al. ®
July/August 2019 Volume 10 Issue 4 e00808-19 mbio.asm.org 6
TRAF3, and TRAF6 were detected in GRA15II immunoprecipitates but were absent in
ROP38I immunoprecipitates (Table 1). We also observed the baculoviral IAP repeat-
containing protein (BIRC2), an E3 ubiquitin-protein ligase know to interact specifically
with TRAF2 and for its antiapoptotic function (Table 1). To validate these observations,
we immunoblotted the immunoprecipitated GRA15II and ROP38I with antibodies
against TRAF2, TRAF3, and TRAF6. We observed a faint band for TRAF3 and a strong
signal for TRAF2 and TRAF6 only in the immunoprecipitated GRA15II (Fig. 3B). To
confirm these interactions in cells infected with parasites, we immunoprecipitated
GRA15 from HEK-293 cells infected with RH parasites expressing HA-tagged GRA15II.
We immunoblotted the immunoprecipitated GRA15II with antibodies against TRAF2
and TRAF6 and observed a strong signal for these TRAF proteins (Fig. 3C). Thus, GRA15II
interacts with host TRAF proteins.
GRA15 TRAF2-binding sites mediate NF-B activation. GRA15 does not have
homology to any known proteins (www.ncbi.nlm.nih.gov/BLAST). However, our bioin-
formatic analysis identified two TRAF2-binding sites ([PSAT]x[QE]E), AAEE160–163 and
SQQE430–433, and one TRAF6-binding site (PxExx[FYWHDE]), PGENSY506–511, in the
GRA15 sequence, which could function as a docking site for TRAF proteins (schematic
in Fig. 2A) (30). The mass spectrometry results also identified two ubiquitination sites
on the GRA15II sequence: lysine 126 and lysine 172 (see Table S1 in the supplemental
material). Therefore, to determine if these putative TRAF2-binding sites and/or the
ubiquitination sites are required for GRA15-dependent NF-B activation, we used Q5
mutagenesis to mutate these sites in the GRA15II full-length sequence. We cloned the
full-length GRA15II-51–550 without the putative signal peptide (schematic of GRA15II in
Fig. 2A), the deletions AAEE160–163, SQQE430–433, and AAEE160–163/SQQE430–433, and
the substitutions K/A126 and K/A172 in a mammalian expression vector. We transiently
transfected the full-length and GRA15 mutants in the HEK293 NF-B luciferase reporter
cell line to determine differences in NF-B activation. We did not observe a significant
difference in NF-B activation for the ubiquitination mutants compared to the full-
length GRA15II-51–550 sequence. However, we observed that the single TRAF2-site
mutants had 60% decrease in NF-B activation compared to full-length GRA15 and
the double TRAF2-site mutant had an 75% decrease in NF-B activation (Fig. 4A). To
ensure that the decrease in NF-B activation was not due to lack of protein expression,
FIG 4 TRAF2-binding sites are required for full NF-B activation. (A) Transient transfections of the NF-B reporter
cell line with GRA15II, mutant for ubiquitinylation sites or TRAF2-binding site mutants. The graph shows the
average percentage of luciferase activity of the mutants compared to GRA15II-51–550 (indicated as WT) across three
independent experiments (n  3), and error bars represent SD. The asterisk indicates significantly higher levels of
luciferase activity compared to GRA15II-51–550. ns, nonsignificant. P  0.0014 for ΔAAEE, P  0.0010 for ΔSQQE, and
P  0.0007 for ΔAAEE/SQQE by one-way ANOVA with Dunnett’s multiple-comparison test. (B) NF-B reporter cell
lines were transiently transfected with the GRA15II mutant for ubiquitinylation sites or TRAF2 binding site mutants
and immunoblotted with antibody against GRA15 (raised against residues 493 to 510) (top panel) and GAPDH
(bottom panel) for the loading control.
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we immunoblotted for GRA15 upon transient transfection of HEK293 cells and
observed that the TRAF2-site GRA15 mutants were similarly expressed to the full-length
GRA15 (Fig. 4B). Thus, the decrease in NF-B activation is specific to the missing
sequences AAEE160–163 and SQQE430–434 in GRA15 sequences and is not because of
protein expression differences. These data are consistent with GRA15 activating NF-B
through recruitment of TRAF proteins via its TRAF-binding domains.
TRAF2 is partially needed for GRA15-mediated NF-B activation. Immunopre-
cipitation performed on TREX-293 cells overexpressing GRA15II demonstrated that
TRAF2 is a binding partner of GRA15. To elucidate the cross talk between GRA15 and
TRAF2, we performed additional experiments, utilizing an HEK293 NF-B–green fluo-
rescent protein (GFP) reporter cell line. We used CRISPR/Cas9 to generate an indel in
TRAF2 (see Fig. S2 in the supplemental material) in this reporter cell line and isolated
a clonal line that no longer expressed TRAF2 (Fig. 5A). Both the wild-type and the TRAF2
knockout reporter lines (Δtraf2) were infected with a type II strain (Pru), a type II Δgra15
strain, and the type I RH strain, which does not express GRA15. (Note that none of these
strains expresses GFP.) To measure the activation of the NF-B pathway, we performed
a quantitative analysis of GFP expression. GFP levels were undetectable in noninfected
and nonstimulated cells. There was a significant (47%) decrease in expression of GFP
between the Δtraf2 and the wild-type cells when they were infected with type II
(Fig. 5B). Infection with the type II Δgra15 or the RH strain did not lead to any GFP
expression. As shown by others (31), Δtraf2 cells were susceptible to TNF-, and all cells
died upon addition of TNF- (not shown), and therefore TNF- did not induce NF-B
activation in these cells (Fig. 5B). These results show that the activation of the NF-B
pathway by GRA15 is partially dependent on TRAF2.
FIG 5 TRAF2 is partially needed for GRA15-mediated NF-B activation. (A) The Western blot shows the
presence of TRAF2 in NF-B reporter wild-type cells and its absence in NF-B reporter Δtraf2 cells
stimulated or not with TNF-. (B) GFP quantitative analysis and comparison between NF-B reporter
wild-type and NF-B reporter Δtraf2 cells under different conditions: US/UI (uninfected/unstimulated),
TNF- stimulation only, infection with Toxoplasma gondii strain Pru, Pru Δgra15, and the RH strain. GFP
expression is reduced by 47% in the NF-B reporter Δtraf2 cells compared to the NF-B reporter wild
type, whereas there is no expression in Pru Δgra15 or RH strain-infected cells. The asterisk indicates
statistically significant results. TNF- stimulation of NF-B reporter wild-type versus NF-B reporter Δtraf2
cells: P  0.0001 by two-way ANOVA with Sidak’s multiple-comparison test.
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DISCUSSION
We observed that upon ectopic expression of either type II or type III GRA15, there
was significant NF-B activation compared to noninduced controls. In contrast, upon
infection of human or murine cells, type II strains strongly activate NF-B, while type III
strains induce very weak or no NF-B activation (14). Thus, it is likely that the low
expression level of GRA15 in type III strains and the presence of type III strain effectors
that have an inhibitory effect, such as ROP38, which is highly expressed in type III
strains and inhibits NF-B and ROP16, which can also inhibit NF-B (19), explain the
absence of NF-B activation by type III strains.
We identified several host proteins that may directly interact with GRA15 or are
present in a complex with GRA15. The most promising interaction partners were TRAFs,
which coimmunoprecipitated with GRA15II ectopically expressed in TREX cells but were
absent in all other immunoprecipitations. TRAF2 and TRAF6 are both involved in the
canonical NF-B activation pathway (32), whereas TRAF2 and TRAF3 are involved in
nonredundant negative regulatory roles in the alternative NF-B activation pathway
(33, 34). Upon exposure to classical activating stimuli such as TNF-, TRAF2 becomes
polyubiquitinated and activates a downstream kinase, RIPK, to cause activation of the
IKK complex (35). Other canonical activating stimuli, such as lipopolysaccharide (LPS),
cause oligomerization of TRAF6 and activation of its E3 ligase activity, which leads to
recruitment and activation of TAK1, a downstream kinase. TAK1 then binds to the
regulatory subunit of the IKK complex to activate IKK/, causing phosphorylation of
IB and allowing nuclear translocation of p65/p50 heterodimers to occur. We ob-
served a faint TRAF3 band in the GRA15 immunoprecipitate in TREX cells, suggesting
that TRAF3 is not a direct interactor of GRA15. TRAF3 was demonstrated to physically
interact with the NF-B-inducing kinase (NIK) and mediate its ubiquitination and
degradation (36). Thus, noncanonical NF-B activation is associated with TRAF3 deg-
radation and concomitant accumulation of NIK (36). Another study demonstrated that
NIK degradation is cross-regulated by a complex consisting of TRAF3/TRAF2/cIAP1/
cIAP2 (34). The GRA15 primary sequence contains two TRAF2 binding motifs
(AAEE160–163 and SQQE430–433) and one TRAF6 binding motif (PGENSY506–511), and we
show that the TRAF2 motifs play a role in GRA15-mediated NF-B activation. Likely, the
remaining activation of NF-B we observed in the double TRAF2 GRA15 mutant is
due to the remaining TRAF6 binding site. Taken together, GRA15 TRAF-binding sites are
functional and likely complementary by recruiting both TRAF2 and TRAF6.
GRA15-mediated NF-B activation seems remarkably similar to what has been
described as the mechanism of NF-B activation by the Epstein-Barr virus (EBV), which
can cause Burkitt lymphoma. EBV encodes the effector LMP1 (latent membrane protein
1), which persistently activates NF-B by mimicking CD40 signaling (37). The CD40
cytoplasmic domain has one TRAF6- and two TRAF2-binding sites, which are important
for its function (38). LMP1 is a six-membrane-spanning molecule that contains two
C-terminal activation (CTAR) domains, CTAR1 and CTAR2, which activate the alternative
and canonical NF-B pathways, respectively. CTAR1 interacts with TRAF2 and TRAF3 to
activate the alternative NF-B pathway, and this alternative activation is dependent on
the TRAF-binding site in CTAR1 (39). On the other hand, CTAR2 interacts with TRAF6,
leading to activation of the canonical NF-B pathway, dependent on eight residues
within CTAR2 (40). Constitutive activation of the NF-B pathway in B-cells, which are the
preferred cell type infected by EBV, leads to the malignant transformation of these cells
(41). Although we previously have seen no evidence of GRA15 activating the alternative
NF-B pathway in human foreskin fibroblasts (14). It is possible that such activation
could take place in different cell types. Interestingly, it has been shown that activation
of CD40 signaling in both hematopoietic and nonhematopoietic cells infected with
Toxoplasma leads to autophagy-mediated destruction of the parasitophorous vacuole
(42). It will be of interest to determine if GRA15 signaling can also affect the autophagy
pathway.
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MATERIALS AND METHODS
Plasmids. The vector pcDNA-LIC-HF was a gift from M. A. Hakimi and A. Bougdour. Primers were
designed to amplify after the predicted signal peptide to the predicted stop codon. Forward primers to
amplify GRA15 (5=-TGGCTGGTGCTGGTGCCCATATAATTCGGTGGCTTGGGTATCTT-3=) together with re-
verse primers (5=-GCTCCGGCTCCTGCCCCAGCTGGAGTTACCGCTGATTGTGTG-3=) contained ligation-
independent cloning (LIC) sequences (in boldface) and were used to amplify GRA15 from PRU (II) and CEP
(III) genomic DNA. Forward primers to amplify ROP38I (5=-TGGCTGGTGCTGGTGCCCATCATGGCAGCAG
CACTGATGGATCAG-3=) together with reverse primers (5=-GCTCCGGCTCCTGCCCCAGCAAATTGATGCGT
TCTTATCCGA-3=) contained LIC sequences (in boldface) and were used to amplify ROP38 from RH
genomic DNA. PCR products were treated with T4 DNA polymerase (using only TTP at 100 mM). The
pcDNA-LIC-HF vector was digested with SmaI and treated with T4 DNA polymerase (using only ATP at
100 mM) to generate long overhangs. The PCR fragment and vector were then annealed for 15 min at
room temperature, generating expression vectors with Toxoplasma genes C-terminally tagged with
HA-FLAG.
The vector pIC242 was a gift from I. Cheeseman (Whitehead Institute, Cambridge, MA). The GRA15II
full-length protein (51 to 550 aa) was amplified and inserted into pIC242 by restriction/ligation,
expressing GRA15II mutants as N-terminal fusion GFP proteins. Expression of GFP fusion proteins was
promoted by the endogenous retroviral long terminal repeats. GRA15 truncation and mutation con-
structs were amplified from the pIC242 GRA15II full-length protein (51 to 550 aa) using specific primers
(Table 2) and confirmed by sequencing.
Inducible TREX-293 cell line construction. The TREX-293 cell line was a gift from J. Niles (MIT,
Cambridge, MA). TREX-293 cells were seeded at 75% confluence and cotransfected with expression
vector pcDNA-LIC-GRA15II-HF or ROP38I-HF and a puromycin resistance vector (ratio of 10:1), using the
X-tremeGENE 9 DNA transfection reagent (Roche). Cells were split 2 days posttransfection and subjected
to puromycin (Calbiochem) selection at 1 g/ml. Foci were picked and expanded at least 1 week
postselection, and positive foci were selected through HA expression using immunofluorescence and
immunoblotting.
Immunofluorescence. TREX-293 cells overexpressing GRA15II or GRA15III were plated at 80% con-
fluence in 24-well coverslip plates, induced with tetracycline (Sigma-Aldrich) at 1 g/ml for 24 h, fixed
with formaldehyde for 20 min, and blocked with blocked with phosphate-buffered saline (PBS) with 3%
(wt/vol) bovine serum albumin (BSA) and 5% (vol/vol) goat serum. Coverslips were incubated with
anti-HA (1:500 [Roche]) and anti-p65 (1:500 [Santa Cruz SC-109]) at 4°C overnight, and fluorescent
secondary antibody and Hoechst stain were used for HA and p65 and DNA visualization, respectively.
Transient transfections. NF-B reporter HEK293 cells (luciferase/GFP) (System Biosciences) were
seeded at 7.5  105 cells per well in a 6-well plate and incubated for 4 h at 37°C. Cells were subsequently
transiently transfected with XtremeGene9 transfection reagent (Roche) with pcDNA-LIC-GRA15II-HF,
GRA15III-HF, or pIC242-GRA15II (full-length and mutants) and incubated for 24 h at 37°C. Cells were lysed
in 100 l Promega Passive lysis buffer, and luciferase activity was measured in lysates according to the
manufacturer’s instructions. Data from conditions with comparable transfection efficiencies were used.
Coimmunoprecipitation. TREX-293 cells overexpressing GRA15II or ROP38I were grown in a T175
flask until 100% confluence and induced with tetracycline (1 g/ml) for 24 h. HEK-293 wild-type cells
were grown in a T175 flask until 100% confluence and infected for 8 h with RH expressing GRA15II. Cells
TABLE 2 GRA15 primers used in this studya
GRA15 truncation or mutation
5=¡3= primer
Forward Reverse
GRA1551–550 CTC GAG ATAATTCGGTGGCTTGGGTATCTT GAA TTC TGGAGTTACCGCTGATTGTGTG
GRA1551–338 GAA TTC TCA ATT TGA GTA CGT
TAA CCT CGC CTC CGT CTC
GRA1551–479 GAA TTC TCA ATG CGG AGA CGA
GAT GGG TTG TGT ACG TGA
GRA1551–517 GAA TTC TCA CTC AGT TGG TAC
AGA GTA GTA AGA GTT TTC
GRA1551–527 GAA TTC TCA CCT TTG GGG ACC
TGG ATC AGA GAT CGT CCG
GRA1580–550 CTC GAG TCC GAC TCA GTG CGG GAA
ACA CGG GAA ACA CGG CGA GGC
GRA15170–550 CTC GAG GAC AGA AAA GTT CCG GAG
GGT GCC CAA CTC
GRA15270–550 CTC GAG CCA ACG GCA CCA GCA CCA
GCG ACC GCC ACT AGC AAC
K/A1126 CGTCAACCGATGGAGCGTCTGAGAGTGAAC TGTCAGCGCCGCAGCCGCCGT
K/A172 GTCCGAGAGACAGAGCAGTTCCGGAGGGTG TCGAAGAGCGTTCTTCCGCCGCCTTGC
ΔAAEE CGCTCTTCGAGTCCGAGAGACAGAAAAG CTTGCGCGTCGCGAATGGGGAA
ΔSQQE CTCCCTGTGGTAGAAAATGCGACTTTC TAGTGGAAGTTGGCTTTGCACGGC
a5= XhoI and 3= EcoRI are in italic. The forward primer sequence common for all the C-terminal truncations and the reverse primer sequence common for all the N-
terminal truncations are in boldface.
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were then scraped in ice-cold PBS. The cells were centrifuged and resuspended them in 1 ml of lysis
buffer (HEPES, 10 mM [pH 7.9]; MgCl2, 1.5 mM; KCl, 10 mM; EDTA, 0.1 mM; dithiothreitol [DTT], 0.5 mM;
NP-40, 0.65%; protease inhibitor cocktail [Roche]; phenylmethylsulfonyl fluoride [PMSF], 0.5 mM) for 30
min at 4°C. The lysate was centrifuged for 30 min at 18,000  g at 4°C. The samples were incubated with
100 or 30 l of magnetic beads coupled with HA antibodies (Thermo Scientific) overnight at 4°C, rotating.
The beads were washed 3 times with Tris-HCl (10 mM [pH 7.5]), NaCl (150 mM), Triton X-100 (0.2%), PMSF
(0.5 mM), and a protease inhibitor cocktail (Roche) and then one more time with Tris-HCl (62.5 mM [pH
6.8]), and the beads were resuspended in 100 or 40 l of this buffer.
Western blotting. Ten percent input lysate and 20 l of the magnetic beads coupled with antibodies
to HA of each sample were used to run SDS-PAGE. The proteins were transferred to a polyvinylidene
difluoride (PVDF) membrane, blocked for 30 min with TBST (Tris-buffered saline with Tween 20)–5%
nonfat dry milk. The membrane was blotted overnight at 4°C with rat antibody against HA (3F10, 1:500
dilution [Roche]) and TRAF2, TRAF3, TRAF6, and lamin A rabbit antibodies (sc-876, sc-1828, sc-7221, and
sc-293162, respectively, 1:200 [Santa Cruz]), followed by respective secondary horseradish peroxidase
(HRP)-conjugated antibodies. NF-B reporter HEK293 cells transfected with GRA15 constructs were lysed
with lysis buffer, boiled for 5 min, and subjected SDS-PAGE. Proteins were transferred to a PVDF
membrane, blocked for 30 min with TBST plus 5% nonfat dry milk, incubated with affinity-purified rabbit
polyclonal antibodies to GRA15 (raised against the peptide with the amino acid sequence of
GRA15493–510, 1 g/ml [YenZym Antibody, San Francisco, CA]) (19) or antibodies against mouse GAPDH
(sc-32233, 1:500 [Santa Cruz]), overnight at 4°C, followed by the respective secondary HRP antibodies.
TREX-293 GRA15II or GRA15III was induced or not with tetracycline (1 g/ml) for 24 h. The cells were lysed
and subjected to SDS-PAGE. After transfer, the PVDF membrane was incubated with rat antibody against
HA (Roche) and mouse GAPDH antibodies (Santa Cruz) for 1 h at room temperature, followed by the
respective secondary HRP-conjugated antibodies. The parasite lysates were lysed and subjected to
SDS-PAGE. After transfer, the PVDF membrane was incubating with rabbit antibody against SAG1 for 1 h
at room temperature, followed by the respective secondary HRP-conjugated antibody.
Mass spectrometry-based proteomics. The magnetic beads coupled with antibodies against HA
were sent to the Proteomic Core Facility of the University of California Davis for mass spectrometry
analysis. Briefly, the proteins were digested using Promega modified trypsin overnight at room temper-
ature on a gently shaking device. The resulting peptides were analyzed by online liquid chromatography-
tandem mass spectrometry (LC-MS/MS) with Q-Exactive. All MS/MS samples were analyzed using X!
Tandem [The GPM, thegpm.org; version X! Tandem Alanine (2017.2.1.4)]. X! Tandem was set up to search
the uniprotHSTG_crap database, assuming the digestion enzyme trypsin. X! Tandem was searched with
a fragment ion mass tolerance of 20 ppm and a parent ion tolerance of 20 ppm. Glu¡pyro-Glu of the
N terminus, ammonia loss of the N terminus, Gln¡pyro-Glu of the N terminus, deamidation of
asparagine and glutamine, oxidation of methionine and tryptophan, dioxidation of methionine and
tryptophan, and dicarbamidomethyl of lysine were specified in X! Tandem as variable modifications.
Scaffold (version Scaffold_4.8.6; Proteome Software, Inc., Portland, OR) was used to validate MS/MS-
based peptide and protein identifications. Peptide identifications were accepted if they could be
established at greater than 50.0% probability by the Scaffold local false-discovery rate (FDR) algorithm.
Peptide identifications were also required to exceed specific database search engine thresholds, and X!
Tandem identifications were also required at least. Protein identifications were accepted if they could be
established at greater than 9.0% probability to achieve an FDR less than 5.0% and contained at least 1
identified peptide. Protein probabilities were assigned by the Protein Prophet algorithm (43). Proteins
that contained similar peptides and could not be differentiated based on MS/MS analysis alone were
grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence were
grouped into clusters.
Construction of a stable NF-B reporter traf2 HEK293 cell line. A TRAF2 knockout cell line was
made in NF-B GFP reporter HEK293 cells (System Biosciences) using CRISPR/Cas9. Wild-type NF-B
reporter HEK293 cells are expressing green fluorescent protein (GFP) when the NF-B pathway is
activated. The vector pSpCas9 (BB)-2A-Puro (PX459) was purchased from Addgene (plasmid 48139).
Guide RNAs (gRNAs) were designed and selected based on MIT’s site CRISPR Design Tool (http://crispr
.mit.edu/). The gRNAs (20 nucleotides in length) were designed to target the first exon of the TRAF2 gene.
The forward gRNA for TRAF2 (5=-CACCGCCTGCAGAAACGTCCTCCGC-3=) and the reverse guide RNA
(5=-AAACGCGGAGGACGTTTCTGCAGGC-3=) were selected as the guides with the lowest score of “off-
target” events. After the appropriate guides were designed, they were cloned into the pSpCas9 (BB)
vector for coexpression with Cas9. All of the procedures were based on the protocol by Ran et al. (44).
NF-B reporter cells were plated at 7 104 cells per well in a 24-well plate and incubated for 24 h at 37°C.
They were then transiently transfected with the guide RNAs/CRISPR/Cas9 plasmid using the
X-tremeGENE 9 protocol as per the manufacturer’s instructions (Roche). At 48 h posttransfection, cells
were plated in a new 24-well plate, and selection with 1 g/ml puromycin was initiated. Cells were left
under puromycin selection for 3 days. On the third day of selection, isolation of the clonal population was
initiated using serial dilution. The clonal population was isolated after 12 days. Sequence analysis of the
genomic DNA detected the insertion of a nucleotide at position 114 of the first exon of TRAF2, and
Western blot analysis further verified the TRAF2 knockout (Fig. S2).
Stable NF-B reporter traf2 cell line infection with Toxoplasma parasites. NF-B reporter
wild-type and NF-B reporter Δtraf2 HEK293 cells were seeded at 80% confluence in a 96-well plate and
incubated for 4 h at 37°C. Subsequently, the cells were infected with the Pru, Pru Δgra15, or RH strain
(multiplicity of infection [MOI] of 2), stimulated with TNF- (20 ng/ml), or left uninfected/unstimulated.
The GFP absorbance of each 96-well plate was measured.
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Statistical analysis. All statistical analyses were performed using Graph Pad Prism version 7.0. All the
data presented are mean standard deviation (SD), and the exact n values are mentioned in each of the
figure legends. For all calculations, P values of 0.05 are considered significant. For a one-variable test
with two groups, the two-way analysis of variance (ANOVA) was used, followed with Sidak’s multiple-
comparison test. For more than three groups with one variable, one-way ANOVA was followed by
Dunnett’s multiple-comparison test.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.00808-19.
FIG S1, TIF file, 0.7 MB.
FIG S2, TIF file, 2.3 MB.
TABLE S1, XLSX file, 0.1 MB.
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